English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

P226 Background/objective: Data on healthcare resource  utilization (RU) in acute stroke will assist in evaluation of  cost-efficacy and cost-effectiveness of new treatments. We present  results of a substudy of resource utilization within GAIN Americas, a  multi-center, randomized, placebo-controlled, phase 3 clinical trial of  the glycine antagonistGV150526 in acute stroke, conducted in the US  and Canada. Previously reported clinical results showed no difference  in clinical outcome by treatment at 3 months.Methods: RU  data included pre-stroke and Month 3 residence and employment status,  hospital length of stay (LOS) by ward type, discharge destination, and  outpatient rehabilitation services. There were no treatment differences  on RU endpoints, so data were combined across treatment groups.Results: The study population comprised 1604 acute stroke  patients (85% ischemic; median age: 72; female: 48%; median NIHSS  score: 12). Case fatality was 13% in hospital, 21% by Month 3. Median  hospital LOS was 9 days (mean=15), including 3 days (mean = 4.5)  in intensive care and 4.5 days (mean=6.8) in step-down. Discharge  destinations included rehabilitation facility (49%), home (27%) and  nursing home (11%). Pre-stroke, 87% lived in own home, but at 3  months only 62% lived at home. Outpatient rehabilitation services  included occupational therapy (31%), physical therapy (39%), speech  therapy (20%) and psychotherapy (2%). Pre-stroke, 21% were employed  full- or part-time; at Month 3, 6% were employed. Of those employed  pre-stroke, 60% reported being unable to work for health reasons at  Month 3.Conclusion: These data describe the social and  economic burden of stroke in a well-defined cohort. Such information  should be valuable to care providers at many levels of the healthcare  system and to health outcomes researchers. Prospective collection of  detailed RU data from a large clinical trial is feasible and  worthwhile.

stroke

Healthcare Resource Utilization in the Three Months after Acute Stroke: A Report on 1604 Patients from the Glycine Antagonist in Neuroprotection (GAIN) Americas Trial